合成生物 2025年季度报告

FORM10-Q SYNLOGIC, INC. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2025, there were11,696,109shares of the registrant’s common stock, par value $0.001 per share, outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make suchforward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and otherfederal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. Insome cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” •our evaluation of strategic alternatives with a goal to enhance stockholder value, including the possibility of a merger ora sale of the Company;•the success of our research and development efforts;•the initiation, progress, timing, costs and results of clinical trials for our product candidates;•the time and costs involved in obtaining regulatory approvals for our product candidates;•the success of our collaborations with third parties; Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future eventsor to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ouractual results, performance or achievements to be materially different from any future results, performance or achievementsexpressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from currentexpectations include, among other things, those listed in the “Risk Factors” section contained in our Annual Report on Form 10-K This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, ourbusiness, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions.Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject touncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. SYNLOGIC, INC.QUARTERLY REPORT ON FORM 10-Q PART I - FINANCIAL INFORMATION Item 1. Financial Statements PART II - OTHER INFORMATION Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSignatures SYNLOGIC, INC. AND SUBSIDIARIESUnaudited Consolidated Balance Sheets(In thousands, except share amounts) SYNLOGIC, INC. AND SUBSIDIARIES SYNLOGIC, INC. AND SUBSIDIARIES Notes to Unaudited Consolidated Financial Statements (1)Nature of Business Organization Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (Synlogic or the Company), is abiopharmaceutical company that applied synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Bioticsare generated from Synlogic’s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drugcandidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, In February 2024, the Company and its board of directors decided to discontinue the Synpheny-3 trial and to conduct acomprehensive review of strategic alternatives. The Company also announced a corporate restructuring that resulted in a reductionin its workforce, leaving o